| First Author | Li Z | Year | 2023 |
| Journal | Oncogene | Volume | 42 |
| Issue | 22 | Pages | 1857-1873 |
| PubMed ID | 37095257 | Mgi Jnum | J:336130 |
| Mgi Id | MGI:7486605 | Doi | 10.1038/s41388-023-02668-9 |
| Citation | Li Z, et al. (2023) The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses. Oncogene |
| abstractText | Prostate cancer (PCa), the second leading cause of death in American men, includes distinct genetic subtypes with distinct therapeutic vulnerabilities. The DACH1 gene encodes a winged helix/Forkhead DNA-binding protein that competes for binding to FOXM1 sites. Herein, DACH1 gene deletion within the 13q21.31-q21.33 region occurs in up to 18% of human PCa and was associated with increased AR activity and poor prognosis. In prostate OncoMice, prostate-specific deletion of the Dach1 gene enhanced prostatic intraepithelial neoplasia (PIN), and was associated with increased TGFbeta activity and DNA damage. Reduced Dach1 increased DNA damage in response to genotoxic stresses. DACH1 was recruited to sites of DNA damage, augmenting recruitment of Ku70/Ku80. Reduced Dach1 expression was associated with increased homology directed repair and resistance to PARP inhibitors and TGFbeta kinase inhibitors. Reduced Dach1 expression may define a subclass of PCa that warrants specific therapies. |
